Company news

Chengdu Olymvax Biopharmaceuticals Inc. Class A (SSE:688319) news

Chengdu Olymvax Biopharmaceuticals Inc. Class A news releases on 6ix. Latest, Feb 22, 2025: Announcement on Voluntary Disclosure of Initiation of Phase I…

View Chengdu Olymvax Biopharmaceuticals Inc. Class A →

Press releases — page 2

Announcement on Voluntary Disclosure of Initiation of Phase I Clinical Trial for Trivalent and Tetravalent Influenza Vaccine (Split Virus, MDCK Cells) and Completion of First Subject Enrollment

February 21, 2025

Announcement on Obtaining Government Subsidy

January 22, 2025

← Newer